MEP10508A - The use of 4-h-1-benzopyran-4-one derivatives as inhibitors of smooth muscle cell proliferation - Google Patents
The use of 4-h-1-benzopyran-4-one derivatives as inhibitors of smooth muscle cell proliferationInfo
- Publication number
- MEP10508A MEP10508A MEP-105/08A MEP10508A MEP10508A ME P10508 A MEP10508 A ME P10508A ME P10508 A MEP10508 A ME P10508A ME P10508 A MEP10508 A ME P10508A
- Authority
- ME
- Montenegro
- Prior art keywords
- smc
- smooth muscle
- flavopiridol
- proliferation
- glycine
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 210000000329 smooth muscle myocyte Anatomy 0.000 title abstract 3
- 230000004663 cell proliferation Effects 0.000 title abstract 2
- 150000004777 chromones Chemical class 0.000 title abstract 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 6
- BIIVYFLTOXDAOV-YVEFUNNKSA-N alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 abstract 4
- 229950010817 alvocidib Drugs 0.000 abstract 4
- 239000004471 Glycine Substances 0.000 abstract 3
- 230000001419 dependent effect Effects 0.000 abstract 3
- 230000035755 proliferation Effects 0.000 abstract 3
- 108091000080 Phosphotransferase Proteins 0.000 abstract 2
- 208000027418 Wounds and injury Diseases 0.000 abstract 2
- 230000015572 biosynthetic process Effects 0.000 abstract 2
- 230000022131 cell cycle Effects 0.000 abstract 2
- 230000006378 damage Effects 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 208000014674 injury Diseases 0.000 abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 2
- 102000020233 phosphotransferase Human genes 0.000 abstract 2
- 230000003389 potentiating effect Effects 0.000 abstract 2
- 208000024248 Vascular System injury Diseases 0.000 abstract 1
- 208000012339 Vascular injury Diseases 0.000 abstract 1
- 238000010171 animal model Methods 0.000 abstract 1
- 210000001367 artery Anatomy 0.000 abstract 1
- 210000004204 blood vessel Anatomy 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000014509 gene expression Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 229940043355 kinase inhibitor Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1
- 210000002460 smooth muscle Anatomy 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 208000019553 vascular disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24338099A | 1999-02-01 | 1999-02-01 | |
US09/468,665 US6399633B1 (en) | 1999-02-01 | 1999-12-21 | Use of 4-H-1-benzopryan-4-one derivatives as inhibitors of smooth muscle cell proliferation |
PCT/US2000/001104 WO2000044362A2 (en) | 1999-02-01 | 2000-01-18 | The use of 4-h-1-benzopyran-4-one derivatives as inhibitors of smooth muscle cell proliferation |
Publications (1)
Publication Number | Publication Date |
---|---|
MEP10508A true MEP10508A (en) | 2010-06-10 |
Family
ID=22918541
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MEP-105/08A MEP10508A (en) | 1999-02-01 | 2000-01-18 | The use of 4-h-1-benzopyran-4-one derivatives as inhibitors of smooth muscle cell proliferation |
Country Status (38)
Country | Link |
---|---|
US (1) | US6399633B1 (cs) |
EP (1) | EP1150746B1 (cs) |
JP (1) | JP4755759B2 (cs) |
KR (1) | KR100793047B1 (cs) |
CN (1) | CN1219556C (cs) |
AP (1) | AP1469A (cs) |
AR (1) | AR042569A1 (cs) |
AT (1) | ATE275428T1 (cs) |
AU (1) | AU777368B2 (cs) |
BG (1) | BG65151B1 (cs) |
BR (1) | BR0007911A (cs) |
CA (1) | CA2360668C (cs) |
CR (1) | CR6448A (cs) |
CZ (1) | CZ300395B6 (cs) |
DE (1) | DE60013555T2 (cs) |
DK (1) | DK1150746T3 (cs) |
EA (1) | EA004786B1 (cs) |
EE (1) | EE04851B1 (cs) |
ES (1) | ES2226792T3 (cs) |
HK (1) | HK1042445B (cs) |
HR (1) | HRP20010521A2 (cs) |
HU (1) | HU229263B1 (cs) |
ID (1) | ID30180A (cs) |
IL (1) | IL144668A (cs) |
ME (1) | MEP10508A (cs) |
NO (1) | NO330512B1 (cs) |
NZ (1) | NZ512822A (cs) |
OA (1) | OA11755A (cs) |
PL (1) | PL197693B1 (cs) |
PT (1) | PT1150746E (cs) |
RS (1) | RS50242B (cs) |
SI (1) | SI1150746T1 (cs) |
SK (1) | SK286747B6 (cs) |
TR (1) | TR200102223T2 (cs) |
TW (1) | TWI273907B (cs) |
UA (1) | UA73110C2 (cs) |
WO (1) | WO2000044362A2 (cs) |
ZA (1) | ZA200105596B (cs) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0102480D0 (en) * | 2001-01-31 | 2001-03-14 | Cyclacel Ltd | Marker |
DK1511734T3 (da) * | 2002-04-17 | 2010-08-02 | Cytokinetics Inc | Forbindelser, præparater og fremgangsmåder |
US7425618B2 (en) | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
US20040082613A1 (en) * | 2002-06-28 | 2004-04-29 | Schneider Michael D. | Modulators of Cdk9 as a therapeutic target in cardiac hypertrophy |
US20040106647A1 (en) * | 2002-06-28 | 2004-06-03 | Schneider Michael D. | Modulators of Cdk9 as a therapeutic target in cardiac hypertrophy |
AU2003273299B2 (en) * | 2002-09-05 | 2010-04-01 | Medimmune, Llc | Methods of preventing or treating cell malignancies by administering CD2 antagonists |
US7563810B2 (en) | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
US8034831B2 (en) | 2002-11-06 | 2011-10-11 | Celgene Corporation | Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies |
WO2004091510A2 (en) | 2003-04-11 | 2004-10-28 | Medimmune, Inc. | Recombinant il-9 antibodies and uses thereof |
ES2458636T3 (es) | 2003-08-18 | 2014-05-06 | Medimmune, Llc | Humanización de anticuerpos |
US20060228350A1 (en) * | 2003-08-18 | 2006-10-12 | Medimmune, Inc. | Framework-shuffling of antibodies |
AU2005299355A1 (en) | 2004-10-27 | 2006-05-04 | Medimmune, Llc | Modulation of antibody specificity by tailoring the affinity to cognate antigens |
EP1869192B1 (en) | 2005-03-18 | 2016-01-20 | MedImmune, LLC | Framework-shuffling of antibodies |
CA2613512A1 (en) | 2005-06-23 | 2007-01-04 | Medimmune, Inc. | Antibody formulations having optimized aggregation and fragmentation profiles |
WO2007010342A1 (en) * | 2005-07-15 | 2007-01-25 | Sahajanand Biotech Private Limited | Implantable medical devices comprising a flavonoid or derivative thereof for prevention of restenosis |
JP2008255008A (ja) * | 2005-07-19 | 2008-10-23 | Tokyo Medical & Dental Univ | 滑膜細胞増殖抑制剤 |
AU2006275514B2 (en) * | 2005-07-29 | 2012-04-05 | Resverlogix Corp. | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices |
EP2292663B1 (en) | 2006-08-28 | 2013-10-02 | Kyowa Hakko Kirin Co., Ltd. | Antagonistic human light-specific human monoclonal antibodies |
PT2118074E (pt) | 2007-02-01 | 2014-03-20 | Resverlogix Corp | Compostos para a prevenção e tratamento de doenças cardiovasculares |
CA2682170A1 (en) | 2007-03-30 | 2008-10-09 | Medimmune, Llc | Antibodies with decreased deamidation profiles |
EP2346837B8 (en) | 2008-06-26 | 2015-04-15 | Resverlogix Corporation | Methods of preparing quinazolinone derivatives |
EP2382194B1 (en) | 2009-01-08 | 2014-03-12 | Resverlogix Corp. | Compounds for the prevention and treatment of cardiovascular disease |
NZ708314A (en) | 2009-03-18 | 2017-08-25 | Resverlogix Corp | Quinazolinones for use as anticancer agents |
BRPI1014956B8 (pt) | 2009-04-22 | 2021-05-25 | Resverlogix Corp | agentes anti-inflamatórios |
US20130225530A1 (en) | 2010-07-12 | 2013-08-29 | Dkfz Deutsches Krebsforschungszentrum | Wogonin for the prevention and therapy of cardiac hypertrophy |
WO2012103165A2 (en) | 2011-01-26 | 2012-08-02 | Kolltan Pharmaceuticals, Inc. | Anti-kit antibodies and uses thereof |
PL2773354T3 (pl) | 2011-11-01 | 2019-12-31 | Resverlogix Corp. | Doustna formulacja o natychmiastowym uwalnianiu dla podstawowych chinazolinów |
CA2880007C (en) | 2012-07-25 | 2021-12-28 | Kolltan Pharmaceuticals, Inc. | Anti-kit antibodies and uses thereof |
SG11201502757QA (en) | 2012-10-09 | 2015-05-28 | Igenica Biotherapeutics Inc | Anti-c16orf54 antibodies and methods of use thereof |
US9765039B2 (en) | 2012-11-21 | 2017-09-19 | Zenith Epigenetics Ltd. | Biaryl derivatives as bromodomain inhibitors |
WO2014080290A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Cyclic amines as bromodomain inhibitors |
JP2016507496A (ja) | 2012-12-21 | 2016-03-10 | ゼニス・エピジェネティクス・コーポレイションZenith Epigenetics Corp. | ブロモドメイン阻害剤としての新規複素環式化合物 |
US10100123B2 (en) | 2013-06-06 | 2018-10-16 | Pierre Fabre Medicament | Anti-C10orf54 antibodies and uses thereof |
RS62189B1 (sr) | 2013-08-26 | 2021-08-31 | Biontech Research And Development Inc | Nukleinske kiseline koje kodiraju humana antitela na sijalil-luis a |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
PT3154583T (pt) | 2014-06-04 | 2021-03-24 | Biontech Res And Development Inc | Anticorpos monoclonais humanos para o gangliósido gd2 |
PL3333191T3 (pl) | 2014-12-11 | 2021-05-04 | Pierre Fabre Médicament | Przeciwciała przeciwko c10orf54 i ich zastosowania |
SI3265123T1 (sl) | 2015-03-03 | 2023-02-28 | Kymab Limited | Protitelesa, uporabe in postopki |
JO3789B1 (ar) | 2015-03-13 | 2021-01-31 | Resverlogix Corp | التراكيب والوسائل العلاجية المعتمدة لمعالجة الامراض المتعلقة بالمتممة |
RU2717829C2 (ru) | 2015-04-20 | 2020-03-26 | Толеро Фармасьютикалз, Инк. | Прогнозирование ответа на альвоцидиб с помощью анализа профиля митохондрий |
DK3527574T3 (da) | 2015-05-18 | 2022-06-27 | Sumitomo Pharma Oncology Inc | Alvocidib-prodrugs, der har øget biotilgængelighed |
BR112018002427A8 (pt) | 2015-08-03 | 2022-10-18 | Tolero Pharmaceuticals Inc | Uso de alvocidib e de azacitidina ou decitabina para tratar câncer e kit e composição farmacêutica contendo as ditas substâncias |
CA3006769A1 (en) | 2015-12-02 | 2017-06-08 | Stcube & Co., Inc. | Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof |
CN108925136B (zh) | 2015-12-02 | 2022-02-01 | 斯特赛恩斯公司 | 特异于糖基化的btla(b和t淋巴细胞衰减因子)的抗体 |
CA3034875C (en) | 2016-08-23 | 2024-05-28 | Eisai R&D Management Co., Ltd. | Combination therapies for the treatment of hepatocellular carcinoma |
WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
WO2018094275A1 (en) | 2016-11-18 | 2018-05-24 | Tolero Pharmaceuticals, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
MA47776A (fr) | 2017-03-16 | 2020-01-22 | Eisai R&D Man Co Ltd | Polythérapies pour le traitement du cancer du sein |
KR20200015602A (ko) | 2017-05-31 | 2020-02-12 | 주식회사 에스티큐브앤컴퍼니 | Btn1a1에 면역특이적으로 결합하는 항체 및 분자 및 이의 치료적 용도 |
US20200131266A1 (en) | 2017-05-31 | 2020-04-30 | Stcube & Co., Inc. | Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1 |
EP3635007A1 (en) | 2017-06-06 | 2020-04-15 | STCube & Co., Inc. | Methods of treating cancer using antibodies and molecules that bind to btn1a1 or btn1a1-ligands |
JP7196160B2 (ja) | 2017-09-12 | 2022-12-26 | スミトモ ファーマ オンコロジー, インコーポレイテッド | Mcl-1阻害剤アルボシジブを用いた、bcl-2阻害剤に対して非感受性である癌の治療レジメン |
CN111630069B (zh) | 2017-10-13 | 2024-05-31 | 勃林格殷格翰国际有限公司 | 针对Thomsen-nouvelle(Tn)抗原的人抗体 |
AU2019306165A1 (en) | 2018-07-20 | 2021-02-25 | Pierre Fabre Medicament | Receptor for vista |
AU2019391097A1 (en) | 2018-12-04 | 2021-05-20 | Sumitomo Pharma Oncology, Inc. | CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer |
US11793802B2 (en) | 2019-03-20 | 2023-10-24 | Sumitomo Pharma Oncology, Inc. | Treatment of acute myeloid leukemia (AML) with venetoclax failure |
CN113559244B (zh) * | 2021-08-02 | 2023-12-26 | 华中科技大学同济医学院附属协和医院 | Ctrp13脂肪因子的新用途 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IN164232B (cs) * | 1986-04-11 | 1989-02-04 | Hoechst India | |
US5284856A (en) * | 1988-10-28 | 1994-02-08 | Hoechst Aktiengesellschaft | Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives |
US5733920A (en) | 1995-10-31 | 1998-03-31 | Mitotix, Inc. | Inhibitors of cyclin dependent kinases |
US5849733A (en) | 1996-05-10 | 1998-12-15 | Bristol-Myers Squibb Co. | 2-thio or 2-oxo flavopiridol analogs |
US5908934A (en) | 1996-09-26 | 1999-06-01 | Bristol-Myers Squibb Company | Process for the preparation of chiral ketone intermediates useful for the preparation of flavopiridol and analogs |
JP2001509805A (ja) | 1997-02-05 | 2001-07-24 | ワーナー−ランバート・コンパニー | 細胞増殖阻害剤としてのピリド〔2,3−d〕ピリミジンおよび4−アミノピリミジン |
-
1999
- 1999-12-21 US US09/468,665 patent/US6399633B1/en not_active Expired - Fee Related
-
2000
- 2000-01-18 DE DE60013555T patent/DE60013555T2/de not_active Expired - Lifetime
- 2000-01-18 PT PT00909918T patent/PT1150746E/pt unknown
- 2000-01-18 BR BR0007911-1A patent/BR0007911A/pt not_active Application Discontinuation
- 2000-01-18 RS YU54401A patent/RS50242B/sr unknown
- 2000-01-18 AT AT00909918T patent/ATE275428T1/de active
- 2000-01-18 OA OA1200100196A patent/OA11755A/en unknown
- 2000-01-18 SK SK1086-2001A patent/SK286747B6/sk not_active IP Right Cessation
- 2000-01-18 ES ES00909918T patent/ES2226792T3/es not_active Expired - Lifetime
- 2000-01-18 KR KR1020017009716A patent/KR100793047B1/ko not_active IP Right Cessation
- 2000-01-18 ID IDW00200101696A patent/ID30180A/id unknown
- 2000-01-18 JP JP2000595666A patent/JP4755759B2/ja not_active Expired - Fee Related
- 2000-01-18 IL IL14466800A patent/IL144668A/xx not_active IP Right Cessation
- 2000-01-18 EA EA200100742A patent/EA004786B1/ru not_active IP Right Cessation
- 2000-01-18 CA CA002360668A patent/CA2360668C/en not_active Expired - Fee Related
- 2000-01-18 EE EEP200100385A patent/EE04851B1/xx not_active IP Right Cessation
- 2000-01-18 SI SI200030517T patent/SI1150746T1/xx unknown
- 2000-01-18 PL PL350735A patent/PL197693B1/pl not_active IP Right Cessation
- 2000-01-18 AP APAP/P/2001/002218A patent/AP1469A/en active
- 2000-01-18 ME MEP-105/08A patent/MEP10508A/xx unknown
- 2000-01-18 WO PCT/US2000/001104 patent/WO2000044362A2/en active IP Right Grant
- 2000-01-18 UA UA2001075481A patent/UA73110C2/uk unknown
- 2000-01-18 CN CNB008032513A patent/CN1219556C/zh not_active Expired - Fee Related
- 2000-01-18 TR TR2001/02223T patent/TR200102223T2/xx unknown
- 2000-01-18 HU HU0200804A patent/HU229263B1/hu not_active IP Right Cessation
- 2000-01-18 EP EP00909918A patent/EP1150746B1/en not_active Expired - Lifetime
- 2000-01-18 DK DK00909918T patent/DK1150746T3/da active
- 2000-01-18 NZ NZ512822A patent/NZ512822A/en not_active IP Right Cessation
- 2000-01-18 CZ CZ20012804A patent/CZ300395B6/cs not_active IP Right Cessation
- 2000-01-18 AU AU32098/00A patent/AU777368B2/en not_active Ceased
- 2000-01-25 TW TW089101215A patent/TWI273907B/zh not_active IP Right Cessation
- 2000-02-01 AR ARP000100420A patent/AR042569A1/es not_active Application Discontinuation
-
2001
- 2001-07-05 NO NO20013335A patent/NO330512B1/no not_active IP Right Cessation
- 2001-07-06 ZA ZA200105596A patent/ZA200105596B/en unknown
- 2001-07-11 HR HR20010521A patent/HRP20010521A2/hr not_active Application Discontinuation
- 2001-07-27 BG BG105751A patent/BG65151B1/bg unknown
- 2001-08-23 CR CR6448A patent/CR6448A/es not_active Application Discontinuation
-
2002
- 2002-05-31 HK HK02104062.3A patent/HK1042445B/zh not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MEP10508A (en) | The use of 4-h-1-benzopyran-4-one derivatives as inhibitors of smooth muscle cell proliferation | |
Schuppan et al. | Hepatic fibrosis: from bench to bedside | |
WO2008073670A3 (en) | Unit dose formulations and methods of treating thrombosis with an oral factor xa inhibitor | |
ATE369817T1 (de) | Vorrichtung zur abgabe von therapeutischen wirkstoffen | |
NO20063373L (no) | CD40-antistoff-formuleringer og fremgangsmater | |
DE69736745D1 (de) | Verfahren zur behandlung von prostaterkrankungen unter verwendung von vitamin-d-formulierungen mit verzögerter und/oder verlängerter wirkstofffreigabe | |
IL172705A0 (en) | Use of [3.2.0] heterocyclic compounds and analogs thereof for the treatment of cancer, inflammation and infectious diseases | |
WO2004110302A3 (en) | Methods of delivering anti-restenotic agents from a stent | |
BRPI0408999A (pt) | comprimidos prensados de multiparticulados de liberação oral prolongada | |
DE602004032149D1 (de) | Oros-push-stick für die kontrollierte abgabe von wirkstoffen | |
NO20043871L (no) | Legemiddelformuleringer med kontrollert frigjoring som inneholder et baererpeptid | |
DE69435318D1 (de) | Therapeutische inhibitoren der zellen der glatten gefässmuskulatur | |
AR026197A1 (es) | Uso de dipiridamol o mopidamol para el tratamiento y prevencion de trastornos de la microcirculacion dependientes de fibrina | |
DK0856312T3 (da) | Anvendelse af trospiumchlorid til fremstilling af et lægemiddel til behandling af blæresygdomme | |
BR0008443A (pt) | Inibidores de aminotransferaseaminoácido-dependente de cadeia ramificada e seuuso no tratamento da retinopatia diabética | |
ATE359798T1 (de) | Verwendungvon dextransulfat zur behandlung von ibmir | |
WO1996006616A1 (en) | Quinazolinone pharmaceuticals and use thereof | |
HK1046094A1 (en) | Ppar delta inhibitors for the treatment of cardiovascular diseases | |
HUP0203486A2 (hu) | Véralvadással összefüggő betegségek megelőzése és kezelése | |
REED et al. | Vascular reactions in chronically inflamed skin: III. Action of histamine, the histamine releaser 48-80, and monoethanolamine nicotinate (Nicamin) | |
Ferrell et al. | The role of the endothelium in mediating the actions of ATP, adenosine and acetylcholine on flow through blood vessels in the rabbit knee joint. | |
Chang et al. | Differential contributions of nitric oxide synthase isoforms at hippocampal formation to negative feedback regulation of penile erection in the rat | |
RU2010144554A (ru) | Средство для предотвращения и/или лечения сосудистых заболеваний | |
Nunes et al. | Vitamins C and E Alter the Response to Coronary Balloon Injury in the Pig | |
IL110888A (en) | Pharmaceutical compositions for the treatment of liver diseases comprising a vasodilating compound |